Should Low-Dose Biophotonic Therapy Have a Role in the Treatment of Type 2 Diabetes (T2DM)

Orien L Tulp — Fri, 07 Feb 2025 00:00:00 +0000

Humans have always instinctively sought daylight and the sun’s rays for many generations while seeking relief from many sorts of illnesses including infectious illnesses, wound healing and other maladies common to man and animals. Sunshine is deemed a reliable source of quanta of photons, a likely physiologic prerequisite for multiple aspects of mammalian health and vitality. Sunlight is known to deliver photonic energy, and while not exactly a reliable cure-all, it may contribute as a healthful adjunct to the healing process.1-3 The oldest references to the benefits of sun therapy were reported on or before 1500 B.C. and as noted, references to multiple beneficial aspects of sun therapy continue to abound today. Although the molecular basis of photon-mediated therapies remain unclear or speculative, it is recognized that emerging findings of UV-derived light from sunlight or in vivo-derived sources now point to a nuclear disruptive element as a central factor in the ultimate wound healing process.

4,5 Depending on the intensity and wave-length of the UV exposure. it appears to impede further local replication of an invasive infectious agent, combined with an enhancement of immunologic responses in the UV- or sunlight-exposed host. Oxygen availability is deemed essential for optimal wound healing, and the associated immune responses are also likely linked at least in part to enhanced oxygen delivery to peripheral tissues.5

International journal of Complementary and Internal Medicine

Should Low-Dose Biophotonic Therapy Have a Role in the Treatment of Type 2 Diabetes (T2DM)